School of Health Sciences, Purdue University, West Lafayette, Indiana, USA.
Theranostics. 2012;2(10):988-98. doi: 10.7150/thno.4818. Epub 2012 Oct 13.
In this study, we evaluated Cu(L1) in two xenografted tumor-bearing (U87MG and MDA-MB-435) animal models to prove the concept that Cu(II)-labeled rhodamine derivatives, Cu(L) (L = L1 - L4) are useful as selective fluorescent probes for tumor imaging. We found that both multidrug resistance (MDR) negative U87MG gliomas and MDR-positive MDA-MB-435 breast tumors could be visualized. Because of tissue attenuation, accurate quantification of tumor uptake was difficult by optical methods. Therefore, (64)Cu(L) (L = L1 - L4) were evaluated to compare their biodistribution properties. It was found that all four (64)Cu radiotracers had a high glioma uptake ((64)Cu(L1): 5.71± 1.43 %ID/g; (64)Cu(L2): 5.98 ± 2.75 %ID/g; (64)Cu(L3): 4.28 ± 1.45 %ID/g; and (64)Cu(L4): 6.25 ± 3.42 %ID/g) with (64)Cu(L1) showing the highest tumor/background ratios. In athymic nude mice bearing MDA-MB-435 breast cancer xenografts, (64)Cu(L4) showed almost identical normal organ uptake to that in the glioma-bearing animals, but its breast tumor uptake (1.26 ± 0.10% ID/g) was significantly lower (p < 0.001) than that in the glioma (6.25 ± 3.42% ID/g) because of MDR Pgps (P-glycoproteins) and MRPs (multidrug resistance-associated proteins) overexpressed in the xenografted MDA-MB-435 breast tumors. Results from cellular staining assays showed that both Cu(L2) and Cu(L4) were able to localize in mitochondria of U87MG cells, and their tumor selectivity was caused by the elevated negative mitochondrial potential in U87MG glioma cells as compared to that in human fibroblast cells. On the basis of these results, it was concluded that Cu(L) (L = L1 - L4) are useful as selective fluorescent probes for cellular staining assays and optical tumor imaging while (64)Cu(L) (L = L1 - L4) have the potential as PET radiotracers for tumor imaging. This study represents a good example of dual modality imaging (PET and optical) using two agents, (64)Cu(L) and Cu(L), with identical chemical composition. Future research will focus on developing new fluorescent probes with longer wavelength and reduced liver uptake.
在这项研究中,我们在两个异种移植肿瘤荷瘤(U87MG 和 MDA-MB-435)动物模型中评估了 Cu(L1),以证明 Cu(II)标记的罗丹明衍生物,Cu(L)(L = L1-L4)可用作肿瘤成像的选择性荧光探针的概念。我们发现,多药耐药(MDR)阴性 U87MG 神经胶质瘤和 MDR 阳性 MDA-MB-435 乳腺癌都可以被可视化。由于组织衰减,光学方法很难准确量化肿瘤摄取。因此,评估了 (64)Cu(L)(L = L1-L4)以比较它们的生物分布特性。结果发现,所有四种 (64)Cu 放射性示踪剂对神经胶质瘤的摄取都很高 ((64)Cu(L1):5.71±1.43%ID/g;(64)Cu(L2):5.98 ±2.75%ID/g;(64)Cu(L3):4.28 ±1.45%ID/g;和 (64)Cu(L4):6.25 ±3.42%ID/g),其中 (64)Cu(L1) 显示出最高的肿瘤/背景比。在患有 MDA-MB-435 乳腺癌异种移植的裸鼠中,(64)Cu(L4) 显示出与神经胶质瘤荷瘤动物几乎相同的正常器官摄取,但由于异种移植 MDA-MB-435 乳腺癌中过度表达的 MDR Pgps(P-糖蛋白)和 MRPs(多药耐药相关蛋白),其乳腺癌摄取 (1.26 ±0.10%ID/g) 明显较低(p <0.001)(6.25 ±3.42%ID/g)。细胞染色分析结果表明,Cu(L2) 和 Cu(L4) 均能定位于 U87MG 细胞的线粒体中,其肿瘤选择性是由于 U87MG 神经胶质瘤细胞的负线粒体电位升高所致与人类成纤维细胞相比。基于这些结果,可以得出结论,Cu(L)(L = L1-L4)可用作细胞染色分析和光学肿瘤成像的选择性荧光探针,而 (64)Cu(L)(L = L1-L4)具有作为肿瘤成像的 PET 放射性示踪剂的潜力。这项研究代表了使用两种具有相同化学组成的试剂 (64)Cu(L) 和 Cu(L) 进行双重模态成像 (PET 和光学) 的一个很好的例子。未来的研究将集中于开发具有更长波长和减少肝脏摄取的新型荧光探针。